Cagrilintide 5MG

Product Overview

Cagrilintide 5MG is a long-acting amylin-analogue research material, supplied as white to off-white lyophilised powder in a 5mg catalogue presentation (SKU CGL5). This page describes the stated research identity and batch-oriented catalogue specification; it does not provide an administration protocol.

Cagrilintide research examines amylin-receptor biology, satiety-related neural signalling and metabolic regulation. Published studies include early clinical development, while the molecular and formulation evidence remains narrower than for established medicines.

Identity and Specifications

• Product: Cagrilintide 5MG
• SKU: CGL5
• Format: White to off-white lyophilised powder
• Synonyms: Cagrilintide, AM833, NN0174-0833
• Catalogue purity specification: ≥99%
• CAS number: 1415456-99-3
• Molecular formula: C194H312N54O59S2
• Molecular weight: 4409 g/mol
• Amount: 5mg

Research Context

The following themes summarise published research on the named molecule or components. They are research contexts, not claims about the supplied ExtolX batch.

Areas of Research

• amylin-receptor pharmacology
• central satiety and energy-regulation signalling
• metabolic biomarker responses
• combination-study design with incretin-pathway compounds

Evidence Quality and Limitations

Evidence includes a phase 2 programme and continuing registered studies. Clinical findings relate to sponsor-manufactured investigational products and cannot be assumed for this ExtolX material.

Regulatory Context

At the review date, ClinicalTrials.gov lists ongoing cagrilintide studies. This ExtolX product is an independent research material, not an authorised medicine or clinical-trial product.

Storage and Handling

Before reconstitution: Keep the lyophilised vial sealed, dry and protected from light at −20°C or below, subject to the batch-specific supplier documentation. Published cagrilintide reference data support frozen storage, but the free-peptide or acetate form of this ExtolX batch has not been confirmed. Allow a cold vial to reach room temperature before opening to reduce condensation.

After reconstitution: Stability depends on the exact salt or formulation, solvent, concentration, pH and container. Prepare only what the validated method requires. If that method supports frozen storage, use single-use aliquots and avoid repeated freeze–thaw cycles. Use clean laboratory technique, avoid vigorous agitation, and record the preparation and storage history. No numerical solution shelf life has been verified for this ExtolX batch.

Compatibility Limitations

Do not infer solubility or stability from another peptide, blend, amount or pharmaceutical formulation. Use small-scale method development and appropriate analytical controls before committing valuable material.

Laboratory Safety

Handle only in an appropriately equipped laboratory by trained personnel. Use a task-specific risk assessment, suitable personal protective equipment and applicable safety documentation. Avoid ingestion, inhalation, skin contact and environmental release, and dispose of waste in accordance with local requirements.

Sources

• MedChemExpress storage references: Cagrilintide and cagrilintide acetate
• Cagrilintide phase 2 trial (PMID 34798060)
• Cagrilintide/semaglutide phase 2 study (PMID 37364590)
• ClinicalTrials.gov: cagrilintide study record

Scientific sources last reviewed: 23 August 2026.

Research Use Agreement & Disclaimer

For laboratory research use only. Not for human or veterinary use. Purchasers are responsible for lawful handling, storage and disposal in accordance with applicable regulations and good laboratory practice. Product information is educational and is not medical advice or evidence of efficacy.